Brief: Quince Therapeutics Exceeds 75% Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-Telangiectasia
03/06/2025 21:23
June 3 (Reuters) - Quince Therapeutics Inc QNCX.O: QUINCE THERAPEUTICS EXCEEDS 75% ENROLLMENT IN PIVOTAL PHASE 3 NEAT CLINICAL TRIAL IN ATAXIA-TELANGIECTASIA Source text: ID:nBw6tyhXca Further company coverage: QNCX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IRulya Therapeutics
See all newsBrief: Quince Therapeutics - Changes Name To Irulya Therapeutics
Brief: Quince Therapeutics - Appoints Brigette Roberts As CEO Effective October 8, 2026
Quince Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update
Quince Therapeutics Q2 net loss widens on acquisition charges